Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy


Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy




This study enrolled men with prostate cancer who had failed hormone therapy (as shown by rising prostate-specific antigen [PSA] levels) and who were about to start a new line of chemotherapy. Blood was drawn prior to the patient receiving chemotherapy and then monthly thereafter for up to 18 months or until disease progression, whichever occurred first. The blood was tested to find circulating tumor cells (CTC) and to count them. The circulating tumor cell levels were studied in relation to the patient`s overall survival. Serum was also collected for PSA testing, and additional blood samples were drawn to test for circulating endothelial cells and RNA was isolated for future gene expression testing.

Study Status: Active, not recruiting


Condition Intervention Phase
Hormone Refractory Prostate Cancer
Prostate Cancer
Procedure: Phlebotomy N/A

Verified by Immunicon March, 2008

Sponsored by: Immunicon
Information provided by: Immunicon identifier: NCT00133900

Study Type: Interventional

Study Design: Cohort, Prospective

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Ken Pienta, MD., Principal Investigator
Derek Raghavan, M.D.., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site